secwatch.observer — SEC 8-K summary
======================================

Issuer:     enGene Therapeutics Inc. (ENGN)
CIK:        0001980845
Form:       8-K
Filed at:   2024-09-10T23:59:59+00:00
Accession:  0000950170-24-105175
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

enGene Q3 net loss $14.1M; cash $257.7M; LEGEND data expected Sept 2024
-----------------------------------------------------------------------

- Net loss $14.1M ($0.32/share) vs $6.0M prior year; operating expenses $16.8M (up from $6.2M).
- Cash and equivalents $257.7M; expects runway into 2027.
- Preliminary LEGEND study data (BCG-unresponsive NMIBC) due by end of September 2024.
- Ron Cooper appointed CEO and board member; Dr. Raj Pruthi promoted to CMO in July 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1980845/000095017024105175/0000950170-24-105175-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1980845/000095017024105175/engn-20240910.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-105175

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer